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The growing international market for unproven stem cell-based
interventions advertised on a direct-to-consumer basis over the
internet (‘‘stem cell tourism’’) is a source of concern because of
the risks it presents to patients as well as their supporters, domestic
health care systems, and the stem cell research field. Emerging re-
sponses such as public and health provider-focused education and
national regulatory efforts are encouraging, but the market con-
tinues to grow. Physicians play a number of roles in the stem cell
tourismmarket and, in many jurisdictions, are members of a regu-
lated profession. In this article, we consider the use of professional
regulation to address physician involvement in stem cell tourism.
Although it is not without its limitations, professional regulation is
a potentially valuable tool that can be employed in response to
problematic types of physician involvement in the stem cell
tourism market.There is a growing international market for unproven stem
cell-based interventions advertised on a direct-to-con-
sumer basis primarily over the internet, a phenomenon
often referred to as ‘‘stem cell tourism’’ (Ryan et al., 2010;
Levine and Wolf, 2012; Regenberg et al., 2009). Studies
have established that clinics around the world are offering
unproven stem cell-based interventions for a vast array of
diseases and conditions, in the absence of robust evidence
of the safety or efficacy of these procedures (Lau et al., 2008;
Ogbogu et al., 2013). Engagement in this market does not
always involve patients traveling out of country, and, as
is discussedmore below, countries such as theUnited States
are seeing a growingmarket and push for use of autologous
stem cell therapies (Munsie and Hyun, 2014; Bianco and
Sipp, 2014).
Patients generally pay for these treatments directly,
without support from public or private health insurance.
Concerns associated with the stem cell tourism market
are numerous and include physical risks to patients
(Amariglio et al., 2009; Thirabanjasak et al., 2010; Dobkin
et al., 2006; Jabr, 2012), financial exploitation of patientsStem Celland their supporters (Zarzeczny et al., 2010), and reputa-
tional risks for the field of legitimate stem cell science
(Wilson, 2009). There are also financial and other
implications for patients’ home health care systems
when patients return from receiving treatment abroad—
or merge back into publicly funded medical systems after
pursuing care in the private market—and require follow-
up care that may prove complex and/or expensive (Snyder
et al., 2011, 2012).
These concerns have not gone unanswered. Responses
include patient education efforts (ISSCR, 2008a; Master
and Caulfield, 2014), guidance focused on stem cell scien-
tists (ISSCR, 2008b; Master and Resnik, 2011), resources
for clinicians (Caulfield et al., 2012), tightening of national
regulation (e.g., in Germany [Stafford, 2009] and China
[Cyranoski, 2009]), and stronger enforcement of existing
regulatory regimes (FDA, 2011). However, recent data indi-
cate that notwithstanding these efforts, the number of
clinics and jurisdictions in which they operate continues
to grow (Ogbogu et al., 2013). Perhaps this result is unsur-
prising given the challenges inherent in regulating and
responding to online markets that tend to be very fluid,
and more time is required to see the long-term effects of
these efforts. However, given the potential risks involved,
it seems worthwhile to simultaneously consider more
direct avenues of response to stem cell tourism.
Physicians play a variety of roles in the stem cell tourism
market and in many jurisdictions around the world are
members of a regulated profession. Here, we propose that
professional regulation may be well placed to respond to
some of the key concerns associated with the challenging
phenomenon of stem cell tourism.
Physician Involvement
Physicians are involved in stem cell tourism in various
capacities, which may trigger professional discipline,
although some types of conduct aremore direct and poten-
tially egregious than others. For example, physicians mayReports j Vol. 3 j 379–384 j September 9, 2014 j ª2014 The Authors 379
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Professional Regulation and ‘‘Stem Cell Tourism’’provide unproven stem cell-based interventions, own and/
or operate a clinic, refer patients to providers located in
other jurisdictions, advertise unproven stem cell-based in-
terventions offered elsewhere, sit as an advisor or member
of a clinic’s medical board, provide information and advice
to patients, provide preprocedure testing and/or follow-up,
and/or, in a research capacity, share stem cell lines with
providers of the unproven therapies.
There are examples from jurisdictions around the world
where physicians have been sanctioned by professional
regulatory bodies for providing unproven stem cell-based
interventions. For example, Dr. Robert Trossel was a physi-
cian licensed in the United Kingdom who provided stem
cell therapy to a number of patients suffering frommultiple
sclerosis at a clinic he was associated with in Rotterdam. A
panel of the General Medical Council (GMC) found his
fitness to practice was impaired due to his misconduct in
relation to his treatment of these patients and directed
his name be erased from the Medical Register (GMC,
2010). The Medical Board of California similarly disci-
plined a physician, Dr. Darryl See, who treated a number
of patients (including a quadriplegic patient, a patient
with neck pain, and a patient with spinal cord injury)
with stem cells. There were various causes for discipline
in that case including gross negligence, repeated negligent
acts, incompetence, and false representations (MBC, 2007).
In another instance, an Australian physician, Dr. Harvey
Tarvydas, was sanctioned by the Medical Board of Queens-
land for purporting to treat a patient suffering from arach-
noiditis with an experimental treatment intended to
stimulate the growth of stem cells. His conduct was found
to contravene the policy regarding unconventional medi-
cal practice in a number of respects including failure to
obtain properly informed consent and failure to properly
assess the patient (MBQ, 2010).
In other cases, physicians have been sanctioned for less
direct involvement, such as advertisement or pre- or post-
treatment interventions. For example, Dr. Wong Yoke
Meng was a licensed physician in Singapore and owner of
two clinics when he was convicted of professional miscon-
duct for misleading advertisements suggesting he was a
specialist in stem cell treatments that were recognized,
effective treatments for arthritis, hypertension, diabetes,
Parkinson’s disease, and cancer (SMC, 2010a). In another
instance, he was convicted of professional misconduct for
advertising stem cell skin therapy and stem cell therapy
for facial and body rejuvenation. The services offered
included escorted tours to foreign clinics as well as pre-
and posttreatment care (SMC, 2010b).
Although theremay be exceptions (e.g.,Munro, 2005), at
present it seems physicians in jurisdictions such as Canada
are perhaps most likely to be involved in more peripheral
capacities than as direct providers of unproven stem cell-380 Stem Cell Reports j Vol. 3 j 379–384 j September 9, 2014 j ª2014 The Abased interventions. In a recent series of interviews con-
ducted by one of the authors (A.Z.) with practicing
physicians and representatives from provincial Colleges
of Physicians and Surgeons in Canada, the two following
types of involvement emerged as most relevant, based on
experience with analogous areas of medical tourism and
complementary and alternative medicine: (1) information
and advice to patients and/or caregivers, and (2) preproce-
dure testing and/or follow-up.
Indeed, a research study examining the decision-making
processes of Canadian medical tourists indicates patients
commonly approached their regular physicians formedical
records or diagnostic tests in preparation for treatment
abroad, which the physicians typically provided (Johnston
et al., 2012). This study highlights broad health policy im-
plications for patients’ home health care systems, particu-
larly where such services are covered by a public health
insurance scheme (e.g., in Canada). It also raises questions
regarding whether this conduct on the part of physicians
could be viewed or interpreted as support for or passive
(or even direct) endorsement of the procedure at issue. Lev-
ine andWolf (2012) present similar data on the experiences
of individuals in the United States who pursued an un-
proven stem cell-based intervention abroad, either for
themselves or for their children. They reported a range of
interactions between patients and their regular physicians,
including no interaction, strenuous objection, positive
endorsement (or outright recommendation), and ambig-
uous advice (Levine and Wolf, 2012). In light of the duties
physicians owe to their patients (Zarzeczny and Caulfield,
2010), it is questionable whether this range of responses
meets physicians’ professional obligations and relevant
standards of practice.
Role of Professional Regulation
As discussed above, in many countries, physicians are
members of a regulated profession and, as such, are subject
to professional discipline. Two main professional regula-
tory models exist: self-regulation through largely autono-
mous professional bodies, and direct regulation by the
state. Professional self-regulation is unique in a number
of respects. Professions are granted the authority to self-
regulate by the state, usually by way of legislation. In other
words, the state devolves its regulatory power to the profes-
sion itself, recognizing the profession has particular exper-
tise required to effectively evaluate and ensure itsmembers’
competence. This devolution of regulatory power is gener-
ally not unconditional, and frameworks (e.g., regarding
constitution of the governing board, disciplinary pro-
cesses, etc.) are typically set out in the empowering legisla-
tion. Self-regulation is generally considered to be a privilege
that demands the professional body act in the public inter-
est, to serve and protect the public (Khaliq et al., 2010).uthors
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imposed directly by the empowering legislation (e.g., Med-
ical Profession Act, 1981, section 69.1) and has been
characterized as a ‘‘social contract’’ based on the values of
professionalism (Sullivan, 2000).
Canada has adopted the self-regulatory model in the
form of provincial medical colleges (Colleges of Physicians
and Surgeons) constituted and run by members of the
medical profession. The colleges are established by provin-
cial legislation and charged with the responsibility of
licensing practitioners, developing standards of practice/
ethics, and professional discipline of members. Profes-
sional regulation of physicians in the United States is com-
plex and multilayered and varies on a state-by-state basis
(Bourgeault and Grignon, 2013), and it is beyond the scope
of this article to provide a comprehensive account. It is suf-
ficient here to note that, in many cases, physicians in the
United States are also subject to some degree of professional
self-regulation.
In other jurisdictions, including China, Mexico, and
India (countries that could be considered top clinic loca-
tions), the practice of medicine is state regulated. Under
these models, the state retains more direct involvement
in the regulation of the profession. In China, for example,
the National Health and Family Planning Commission of
the People’s Republic of China is responsible for regulating
physicians in accordance with the Administrative Mea-
sures on the Clinical Application of Medical Technology.
In Mexico, the Ministry of Health and the state govern-
ments, in coordination with the relevant educational
authorities, have responsibility under the General Health
Act for monitoring health professionals in the provision
of their respective services. In India, the responsibility for
professional regulation ofmedical practice is shared among
the states and the federal government (via the Medical
Council of India, through The Indian Medical Council
Act), with some roles and responsibilities overlapping.
Regardless of the precise nature of the regulatory model
in place in a particular jurisdiction, they all generally pro-
vide a mechanism by which physicians involved in the
market for unproven stem cell-based therapies could be
monitored and, perhaps, sanctioned for inappropriate
conduct.
Benefits
One of the key reasons professional regulation could be
a valuable oversight tool in this area is its focus on
serving the public interest and/or protecting the public.
This mandate makes professional discipline a particularly
appropriate tool for responding to conduct on the part of
physicians thatmay exposemembers of the public to unac-
ceptable levels of risk.
Professional discipline also generally has a broad range of
responses available to it, particularly as compared to theStem Celljudicial process in either the criminal or civil law contexts.
Possible remedies typically include communication be-
tween affected parties, continuing education, fines, restric-
tions, and suspensions or revocations of practice permits or
licenses. For example, Dr. Tarvydas (discussed above) was
barred from applying for reregistration for 3 years, at which
time he also would have been required to complete
continuing education regarding conventional and uncon-
ventional treatment regimes (MBQ, 2010). This range of
potential responses provides disciplinary bodies with
considerable flexibility to tailor results to the circumstances
at hand—a valuable attribute in a socially complex area like
stem cell tourism.
Indeed, the fact-driven, case-by-case approach is another
benefit of the professional disciplinary process. One of the
difficulties associated with contemplating broad policy re-
sponses (e.g., restrictive legislation) to issues such as stem
cell tourism is the speed with which the science and the
market canmove, given that the relevant context, informa-
tion, and available data can shift fairly quickly (e.g., clinics
moving to different countries, results from a clinical trial
highlighting either safety or clear risks, and publication
of a new case study of adverse events from a particular treat-
ment protocol). By contrast, in a professional disciplinary
action, the decision makers consider the specific facts
before them, in the context of the information and evi-
dence as it existed at the time. This approach may be
especially useful for determining what was and was not
acceptable conduct on the part of a physician in a partic-
ular situation. For example, in the case of Dr. Trossel
(described above), the Fitness to Practice Panel heard expert
evidence when considering whether Dr. Trossel’s treatment
had the rigor required for a medical practitioner to embark
on pioneering treatment, which the panel found it did not
(GMC, 2010).
The long reach of professional regulatory bodies’ juris-
diction is another strength in this context. Patients who
suffer harm as a result of a medical tourism experience
may face significant hurdles in accessing traditional medi-
cal malpractice regimes via the civil litigation route,
regardless of whether they seek to pursue an action in their
home jurisdiction or in the jurisdiction where they
received treatment (Cohen, 2010). By contrast, many pro-
fessional regulatory bodies will exercise authority over
their members regardless of where care is provided. For
example, in the case of Dr. Trossel, the GMC determined
that even where care was provided in the Netherlands, it
had jurisdiction because Dr. Trossel was registered with it
at the time.
Challenges
The application of professional regulation is, however, not
without its challenges. There is considerable variation
worldwide in the manner in which regulatory regimes areReports j Vol. 3 j 379–384 j September 9, 2014 j ª2014 The Authors 381
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conduct, practice, or ethics; and the bounds of disciplinary
authority, not to mention differences in political environ-
ments and the will to enforce existing regimes (e.g., De
Vries et al., 2009) as well as in the financial support avail-
able to fund the regulatory bodies charged with enforcing
professional regulations (Arellano, 2012). There are also
differences of opinionwithinmedical and legal professions
regarding the boundaries of medical practice and accept-
able contexts for use of experimental procedures such as
autologous use of adult stem cells (e.g., Chirba and Gar-
field, 2011; ISSCR, 2013). For example, the OregonMedical
Board issued an order of emergency suspension in the case
of Dr. Kenneth Welker, a physician whose conduct in rela-
tion to a number of different patients was brought into
question, including his provision of autologous stem cell
treatments (‘‘fat transfers’’) (OMB, 2014).
Considerable debate on the issue of autologous stem
cell transplants has taken place in the United States, partic-
ularly surrounding the Texas Medical Board’s approval of
new rules regarding stem cell procedures using adult
stem cells (Park, 2012). Similar debates have occurred in
Australia, amidst recent efforts to encourage self-regulation
of providers of autologous stem cell-based interventions
(Tuch and Wall, 2014). It has been suggested that the
sale of autologous stem cell therapies contravenes physi-
cians’ professional and ethical duties and that preventative
regulation of this area may be appropriate (Munsie and
Hyun, 2014). However, perspectives regarding the appro-
priateness and respective merits of proactive versus
reactive regulatory approaches also appear widely varied
both between and within jurisdictions, which could
impact the ultimate likelihood of new policy approaches
in this area.
One potential concern is that jurisdictional variation in
regulatory approaches and enforcement strategies could
lead to forum shopping by clinics looking for the most
permissive regulatory environment. For example, robust
enforcement efforts in one jurisdiction could drive clinics
(and thereby patients) into less regulated jurisdictions.
Indeed, there is some evidence to suggest this type of
jurisdiction hopping is already occurring in the stem cell
tourism arena following state-level action to restrict this
market (e.g., Mendick, 2012; Berfield, 2013).
The complaint-driven nature of many professional disci-
pline structures may also serve to limit their utility in
this area. The degree to which individuals are aware of
the option tomake a complaint remains an open question,
as does what motivates patients to make a formal
complaint, particularly given that financial compensation
is not generally available as a possible result (unlike
civil litigation). The international dimension of medical
tourism may further complicate the complaint process.382 Stem Cell Reports j Vol. 3 j 379–384 j September 9, 2014 j ª2014 The AFor example, language barriers, cultural differences in ex-
pectations regarding standards of care, and geographic sep-
aration are but a few potential hurdles for prospective
complainants when dealing with a complaint process in
another country. In the absence of a significant number
of complaints from patients or enquiries from physicians
or both, it alsomay be difficult to focus the attention of reg-
ulatory bodies and policymakers on this area.
A lack of clarity on the meaning of some key concepts
involved in this treatment context may also contribute to
ambiguity from the perspective of patients, physicians,
and regulators alike. For example, while it can be ethically
permissible to offer patients innovative and experimental
treatments, this should generally only be done under
particular circumstances, with some preclinical evidence
of safety and efficacy, and after weighing risks and benefits
on a case-by-case basis (Lindvall and Hyun, 2009). It is not,
however, generally permissible to market unproven or
experimental therapies directly to the public as a routine
treatment option or on a for-profit basis (see Munsie and
Hyun, 2014). Improved clarity around concepts such as
medical innovation, compassionate care, and experi-
mental treatment may go a long way toward resolving
this ambiguity (Patenaude et al., 2008).
Inmany cases, professional regulatory bodies have a cen-
tral role to play in providing this type of guidance to their
members. For example, the College of Physicians and Sur-
geons of Ontario has a detailed practice policy regarding
complementary/alternative medicine that clarifies expec-
tations for physician conduct (CPSO, 2011). Similar guid-
ance on the issue of stem cell tourism, perhaps as a subset
of other aspects of medical tourism, may prove a useful
resource. A related challenge relates to limitations in the
kind of stem cell expertise that may be required for disci-
plinary bodies to assess whether a particular intervention
is or is not appropriate given the current state of knowledge
in the field. Any such limitations would not be insur-
mountable, however, and could be answered by consulta-
tions with relevant experts.
Conclusions
Although there are undoubtedly hurdles and challenges
that would need to be addressed, professional regulation
could be an important and powerful tool in responding
to some of the key concerns associated with stem cell
tourism. As we have seen, it has already been deployed in
several jurisdictions throughout the world. And while
these actions did not necessarily result in the removal of
a provider from the scene (many simply move to another
jurisdiction [Ogbogu et al., 2013]), it nevertheless helps
to encourage the development of a practice standard and,
possibly, professional norms that may help over the long-
term to dissuade clinicians from providing unprovenuthors
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from participation in other potentially concerning aspects
of this market.
Ideally, there should be cooperation and sharing of infor-
mation between regulatory bodies at both national and
international levels on approaches to this and other analo-
gous issues. While we recognize it may be difficult to
achieve, coordinated action could work to limit the issue
of jurisdiction hopping (i.e., movement of clinics and
providers to less regulated jurisdictions). In addition, regu-
latory bodies should work closely with the international
stem cell research community to ensure that policy deci-
sions are appropriately informed by the latest scientific
and clinical developments in the field.
Stem cell tourism remains a tremendously complex pol-
icy challenge. Despite years of debate and a range of policy
responses, there is little evidence that the number of clinics
is diminishing or that interest in this area is waning. Given
the potential for harm to patients, the public, and the field
of stem cell research, it seems entirely appropriate to use all
available regulatory and policy tools to mitigate the risks
involved.
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